Arrow Contemplates Fate Of LVAD Business; WorldHeart, Thoratec Start Trials
This article was originally published in The Gray Sheet
Executive Summary
Arrow International's board of directors will assess the future commercial potential of its left-ventricular assist devices at a meeting April 6-7
You may also be interested in...
WorldHeart RELIANT trial
Oakland, Calif.-based company reported Feb. 21 that 20 clinical centers and 29 patients have enrolled in its RELIANT destination therapy trial, which pits the Novacor pulsatile LVAD against Thoratec's HeartMate. WorldHeart anticipates that the additional centers will accelerate patient enrollment for the 390-patient trial. Thoratec's device is the only LVAD approved as a destination therapy for in the U.S. (1"The Gray Sheet" March 28, 2005, p. 17)...
WorldHeart RELIANT trial
Oakland, Calif.-based company reported Feb. 21 that 20 clinical centers and 29 patients have enrolled in its RELIANT destination therapy trial, which pits the Novacor pulsatile LVAD against Thoratec's HeartMate. WorldHeart anticipates that the additional centers will accelerate patient enrollment for the 390-patient trial. Thoratec's device is the only LVAD approved as a destination therapy for in the U.S. (1"The Gray Sheet" March 28, 2005, p. 17)...
People In Brief
Rita Medical: Fremont, Calif. company engages executive search firm Stuart Spencer to assist in recruiting new CFO to replace outgoing exec Donald Stewart, who plans to resign as soon as a suitable substitute is found. Stewart served as Rita's interim CEO during 2003 and was a senior member of the firm's integration team during its merger with Horizon Medical Products last year (1"The Gray Sheet" May 17, 2004, p. 21). Rita sells radiofrequency ablation systems using disposable needles under the Starburst brand and vascular access devices including the Vortex ports...